Cervical Cancer: Symptoms, Causes & Treatment

Cervical cancer is the fourth most common cancer in women globally, with over 600,000 new cases and 340,000 deaths annually — the vast majority in low- and middle-income countries where screening programs and HPV vaccination remain inaccessible. Human papillomavirus (HPV) causes more than 99% of cervical cancers; high-risk genotypes 16 and 18 alone account for approximately 70% of cases. Because HPV infection is necessary but not sufficient for cancer development, persistent infection in combination with cofactors (smoking, immunosuppression, prolonged oral contraceptive use) drives malignant transformation.

Carcinogenesis is a slow, multi-step process: HPV-infected cells progress through cervical intraepithelial neoplasia (CIN I → CIN II → CIN III → carcinoma in situ → invasive cancer) over a median of 10–20 years, providing a critical window for detection and intervention. The transformation zone — where the endocervical columnar epithelium meets the ectocervical squamous epithelium — is the primary site of origin. Squamous cell carcinoma accounts for 70–80% of cases; adenocarcinoma for 20–25%.

Survival is strongly stage-dependent: 5-year survival exceeds 80–90% for Stage I disease but drops to under 20% for Stage IVB. HPV vaccination (bivalent, quadrivalent, or 9-valent) administered before sexual debut confers over 90% protection against high-risk HPV types and represents the most impactful cervical cancer prevention tool available.

• Post-coital bleeding, intermenstrual bleeding, or postmenopausal bleeding — most common presenting symptom
• Abnormal vaginal discharge (bloody, watery, foul-smelling)
• Pelvic pain or low back pain in locally advanced disease
• Dyspareunia (painful intercourse)
• Leg edema or urinary symptoms from lymph node involvement or bladder invasion

• Persistent high-risk HPV infection (genotypes 16, 18, 31, 33, 45) — necessary in 99%+ of cases
• Smoking doubles cervical cancer risk by impairing local immune surveillance
• Immunosuppression: HIV infection (10× risk), organ transplant recipients
• Sexual history: multiple partners and early coitarche increase HPV exposure probability
• Prolonged oral contraceptive use (>5 years) modestly increases risk

Cervical cytology (Pap smear) detects pre-cancerous changes (CIN); co-testing with HPV genotyping improves sensitivity. Colposcopy with directed biopsy confirms histological diagnosis. MRI pelvis delineates local tumor extent; CT chest/abdomen and PET-CT assess lymph node and distant spread. Staging follows the 2018 FIGO classification (clinical + imaging). Cone biopsy or LEEP for CIN III/carcinoma in situ provides diagnostic and therapeutic benefit.

Early-stage (IA-IIA): radical hysterectomy with pelvic lymph node dissection or primary chemoradiation (external beam + brachytherapy with concurrent cisplatin) achieve equivalent outcomes. Fertility-sparing radical trachelectomy for selected Stage IA2-IB1. Advanced-stage (IIB-IVA): concurrent chemoradiation is standard. Metastatic/recurrent disease: pembrolizumab + chemotherapy ± bevacizumab (per KEYNOTE-826) significantly improves survival in PD-L1-positive tumors. Brachytherapy is a key component of curative-intent radiotherapy.

• Local invasion of bladder, rectum, or pelvic side wall in advanced disease
• Lymph node and distant metastases (lung, liver, bone) in Stage IV
• Infertility when hysterectomy is required
• Radiation complications: vaginal stenosis, radiation cystitis, proctitis, lymphedema

• HPV vaccination: 9-valent vaccine (Gardasil 9) — 2 doses for ages 9–14; 3 doses for 15–26; catch-up vaccination up to age 45 in shared clinical decision-making
• Regular cervical screening: Pap smear every 3 years from age 21; co-testing (Pap + HPV) every 5 years from age 25–30 (guidelines vary by country)
• Consistent condom use reduces HPV transmission risk
• Smoking cessation and HIV prevention/treatment